Document is current
Any future updates will be listed below
-
Authors
Edoo, Zainab
Grosse, Camille
Maitre, Thomas
Frita, Rosangela
Chauffour, Aurélie https://orcid.org/0000-0002-8846-5069
Fournier Le Ray, Laure
Godmer, Alexandre https://orcid.org/0000-0002-5211-5796
Aubry, Alexandra
Bourotte, Marilyne
Antoine, Rudy https://orcid.org/0000-0002-7369-0626
Tawk, Lina
Slupek, Stéphanie
Trebosc, Vincent https://orcid.org/0000-0002-8961-1371
Schellhorn, Birgit
Dreneau, Aurore
Hofmann, Line
Kemmer, Christian
Lociuro, Sergio
Dale, Glenn E.
Jung, Françoise https://orcid.org/0009-0002-2731-0327
Pérez-Herrán, Esther https://orcid.org/0000-0002-4464-9528
Mendoza, Alfonso https://orcid.org/0000-0003-2493-4118
Rebollo López, Maria Jose
Ghidelli-Disse, Sonja
Werner, Thilo
Ballell, Lluis
Barros-Aguirre, David https://orcid.org/0000-0002-4099-0438
Mathys, Vanessa https://orcid.org/0000-0001-5218-927X
Soetaert, Karine
Megalizzi, Véronique
Wintjens, René https://orcid.org/0000-0002-0234-7847
Gitzinger, Marc
Deprez, Benoit https://orcid.org/0000-0002-2777-4538
Veziris, Nicolas
Remuiñán, Modesto J.
Willand, Nicolas
Pieren, Michel
Baulard, Alain R. https://orcid.org/0000-0002-0150-5241
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (853800)
Agence Nationale de la Recherche (Mustart ANR-20-PAMR-0005)
Région Hauts-de-France (2108838)
- License Information
-
More Information
Article History
Received: 7 March 2025
Accepted: 17 March 2026
First Online: 7 April 2026
Competing interests
: M.B., V.T., B.S., A.D., L.H., C.K., S.L., G.E.D., F.J., M.G., and M.P. are current or former BioVersys employees and hold stocks or stock options in the company. Z.E and R.F. are former BioVersys employees. The Sorbonne Université Team (A.C., L.F., Th.M., A.G., N.V., A.A.) has received a research grant from BioVersys for conducting preclinical studies on Alpibectir/Ethionamide, and is involved in the Respiri-NTM IMI-AMR project in collaboration with BioVersys. T.W. and S.G.D. are current Cellzome GmbH (a GSK company) employees and hold stocks or stock options in GSK. D.B-A., M.J.R., A.M-L., and L.B. are current or former GSK employees and hold stocks or stock options in the company. M.J.R.L. is former GSK employee. N.W., B.D., M. J. R., E. P-H, and M.B. are listed as co-inventors on patent WO 2019/034700 Al entitled “Novel compounds.” N.W. and A.R.B. are consultants for BioVersys. B.D. is paid as scientific co-director of Institut Pasteur de Lille. A.R.B. team and the research unit U1177 - Drugs and Molecules for Living Systems received research funding from BioVersys. The remaining authors have no competing interest to declare.
